Intra-Cellular Therapies Inc. (ITCI) Stock Rating Reaffirmed by BTIG Research
Intra-Cellular Therapies Inc. (NASDAQ:ITCI)‘s stock had its “buy” rating restated by research analysts at BTIG Research in a research note issued on Friday. They presently have a $36.00 target price on the biopharmaceutical company’s stock. BTIG Research’s price target indicates a potential upside of 68.30% from the stock’s current price.
A number of other equities research analysts have also recently commented on the company. Cantor Fitzgerald set a $29.00 price objective on Intra-Cellular Therapies and gave the stock a “buy” rating in a research note on Thursday, May 11th. Leerink Swann raised Intra-Cellular Therapies from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 23rd. ValuEngine cut Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Zacks Investment Research raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Tuesday, May 16th. Finally, BidaskClub cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $27.11.
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) traded down 3.21% during midday trading on Friday, hitting $21.39. The stock had a trading volume of 828,691 shares. Intra-Cellular Therapies has a one year low of $7.85 and a one year high of $45.20. The firm’s 50-day moving average price is $13.66 and its 200-day moving average price is $12.79. The firm’s market capitalization is $928.84 million.
Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.33. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. The business had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same period in the previous year, the firm earned ($0.71) earnings per share. The firm’s quarterly revenue was down 52.2% compared to the same quarter last year. On average, equities analysts predict that Intra-Cellular Therapies will post ($2.36) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/08/intra-cellular-therapies-inc-itci-stock-rating-reaffirmed-by-btig-research.html.
A number of large investors have recently bought and sold shares of the business. Teachers Advisors LLC grew its stake in Intra-Cellular Therapies by 0.6% in the fourth quarter. Teachers Advisors LLC now owns 70,948 shares of the biopharmaceutical company’s stock valued at $1,071,000 after acquiring an additional 443 shares during the period. American International Group Inc. grew its stake in Intra-Cellular Therapies by 7.1% in the first quarter. American International Group Inc. now owns 21,130 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 1,396 shares during the period. Russell Investments Group Ltd. grew its stake in Intra-Cellular Therapies by 3.8% in the first quarter. Russell Investments Group Ltd. now owns 38,357 shares of the biopharmaceutical company’s stock valued at $623,000 after acquiring an additional 1,402 shares during the period. Rhumbline Advisers grew its stake in Intra-Cellular Therapies by 3.5% in the second quarter. Rhumbline Advisers now owns 43,296 shares of the biopharmaceutical company’s stock valued at $538,000 after acquiring an additional 1,455 shares during the period. Finally, Nationwide Fund Advisors grew its stake in Intra-Cellular Therapies by 8.1% in the second quarter. Nationwide Fund Advisors now owns 27,928 shares of the biopharmaceutical company’s stock valued at $347,000 after acquiring an additional 2,099 shares during the period. 71.79% of the stock is owned by hedge funds and other institutional investors.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.